![Steven D. Targum](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven D. Targum
Chief Tech/Sci/R&D Officer at
Functional Neuromodulation Ltd.
Profile
Steven D.
Targum is the founder of PharmaStar LLC.
He is currently the Chief Medical Officer at Functional Neuromodulation Ltd. His former positions include Vice Chairman-Mental Health Sciences Department at Hahnemann University, Executive-in-Residence at Oxford Bioscience Partners, Chief Medical Officer at BrainCells, Inc. and MSI Methylation Sciences, Inc., and Consultant at The General Hospital Corp.
He received his undergraduate degree from Colgate University and his doctorate from Icahn School of Medicine at Mount Sinai.
Steven D. Targum active positions
| Companies | Position | Start |
|---|---|---|
Functional Neuromodulation Ltd.
 Functional Neuromodulation Ltd. Medical SpecialtiesHealth Technology Develops deep brain stimulation therapies for memory and cognitive disorders | Chief Tech/Sci/R&D Officer | - |
Former positions of Steven D. Targum
| Companies | Position | End |
|---|---|---|
Hahnemann University
 Hahnemann University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 1994-12-31 |
PharmaStar LLC
 PharmaStar LLC Miscellaneous Commercial ServicesCommercial Services Provides training services for medical researchers | Founder | - |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services Functions as a non profit organization that operates general hospital | Corporate Officer/Principal | - |
MSI Methylation Sciences, Inc.
 MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products through compound leverage | Chief Tech/Sci/R&D Officer | - |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Private Equity Investor | - |
Training of Steven D. Targum
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
8
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
BrainCells, Inc.
 BrainCells, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products through compound leverage | Health Technology |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services Functions as a non profit organization that operates general hospital | Health Services |
Colgate University
 Colgate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PharmaStar LLC
PharmaStar LLC Miscellaneous Commercial ServicesCommercial Services Provides training services for medical researchers | Commercial Services |
Icahn School of Medicine at Mount Sinai
 Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hahnemann University
Hahnemann University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Functional Neuromodulation Ltd.
Functional Neuromodulation Ltd. Medical SpecialtiesHealth Technology Develops deep brain stimulation therapies for memory and cognitive disorders | Health Technology |
- Stock Market
- Insiders
- Steven D. Targum
